<DOC>
	<DOCNO>NCT00464698</DOCNO>
	<brief_summary>The purpose study assess efficacy Duloxetine treatment obsessive compulsive disorder .</brief_summary>
	<brief_title>Duloxetine Treatment Obsessive Compulsive Disorder ( OCD )</brief_title>
	<detailed_description>Obsessive compulsive disorder affect approximately 3 % population . Treatment option include selective serotonin reuptake inhibitor ( SSRIs ) , dual serotonin norepinephrine reuptake inhibitor ( SNRIs ) , behavioral therapy . Duloxetine new SNRI . This study aim assess efficacy duloxetine treatment OCD . Before subject give write informed consent , make aware alternative participation study , include independently seek pharmacotherapy cognitive behavioral treatment OCD . Patients begin open-label treatment duloxetine 30 mg/day see one week ( Visit 2 ) . At Visit 2 , patient assess , experience significant side effect , dose increase 60 mg/day . Patients experience significant side effect 30 mg/day discontinue study offer standard treatment clinic . Patients take 60 mg/day return assessment four week ( Visit 3 ) . At time , experience significant side effect , dose increase 120 mg/day . Patients unable tolerate 120 mg/day dose decrease back 60 mg/day continue trial . End study final statistical analysis conduct include exclude patient . Remaining assessment every 4 week ( Visits 4 , 5 , 6 ) . Thus , total 17-week study 12 week high dose believe necessary response . At visit follow initial visit , patient assess use Y-BOCS , BDI , BAI , CGI . The Q-LES-Q administered initial last visit . The study procedure similar standard medical treatment OCD MGH . Like standard care , participant start low dose medication increase dose maximally tolerate level . Barring significant side effect , patient remain dose 4-8 week provide medication adequate trial period . At end period , efficacy would assess alternative would discuss . One difference study standard care study provide assessment verbal write scale . This additional assessment could greatly benefit patient decide treatment option . Another difference participant involve current behavior therapy throughout study . Many patient choose pursue medical treatment without behavior therapy standard care ; however , standard care , option pursue concurrently pursue behavior therapy . If patient wish pursue behavior therapy receive medication therapy concurrently , form treatment MGH might appropriate . If want medical treatment , study similar standard care lower cost .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Diagnosis OCD DSMIV Age 1865 YBOCS great 20 Written inform consent Females childbearing potential must negative serum urinary betaHCG test . Pregnant woman woman childbearing potential use medically accept mean contraception . Patients , investigator 's judgment , pose serious suicidal homicidal risk . Serious unstable medical illness include cardiovascular ( include hypertension ) , hepatic , renal , respiratory , endocrine , neurologic , hematologic disease . Patients anticoagulant therapy . History seizure disorder Comorbid bipolar disorder , psychosis , organic mental disorder , developmental disorder If history substance abuse , patient remission least 6 month . Currently treat behavioral therapy , specifically exposure response prevention , OCD . Other medication medical disorder may interfere duloxetine Current major depression prescribe antidepressant major depression within past 12 month . We assess depressive symptom BDI throughout course study order ass subsyndromal depressive symptom assess emergence depressive symptom . Taken psychotropic medication within 2 week begin study ( 4 week fluoxetine ) . More 1 adequate trial ( least 10 week maximally tolerate dose ) another SSRI past . Known hypersensitivity duloxetine inactive ingredient . Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day randomization potential need use MAOI drug study within 5 day discontinuation study drug . Patients uncontrolled narrowangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OCD</keyword>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>Obsessions</keyword>
	<keyword>Compulsions</keyword>
	<keyword>Duloxetine</keyword>
	<keyword>Cymbalta</keyword>
</DOC>